The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.
American Headache Society Annual Scientific Meeting (AHS)
Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.
Advertisement
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose
5